Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM, , Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial., Lancet, 2007, 369, 9561, 559-570, doi: 10.1016/S0140-6736(07)60200-1.
Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ, , Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study., Lancet Oncol., 2012, 13, 4, 420-432, doi: 10.1016/S1470-2045(11)70328-X.
Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C, , A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer., N. Engl. J. Med., 2004, 350, 11, 1081-1092, doi: 10.1056/NEJMoa040331.
Fallowfield LJ, Kilburn LS, Langridge C, Snowdon CF, Bliss JM, Coombes RC, , Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation., Br. J. Cancer, 2012, 106, 6, 1062-1067, doi: 10.1038/bjc.2012.43.